Clinical trial
Phase II Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients With COPD
NCT00671073 is registered in ClinicalTrials.gov with Forest Laboratories as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase II Dose-Ranging Study of the Efficacy and Safety of Oglemilast in Patients With COPD
- Lead sponsor
- Forest Laboratories
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- May 5, 2008
- Completion date
- May 15, 2009
- Enrollment
- 427 (actual)
- Sites
- 47
Conditions
As the registry lists them; a condition with its own page is linked.